Tag Archives: Boris Peaker

Analysts Have Conflicting Sentiments on These Healthcare Companies: Tesaro (NASDAQ: TSRO) and Loxo Oncology (NASDAQ: LOXO)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Tesaro (NASDAQ:TSRO) and Loxo Oncology (NASDAQ:LOXO). Tesaro (TSRO) Cowen & Co. analyst Boris Peaker maintained a Hold rating on Tesaro today and set

Argenx Se (ARGX) Received its Third Buy in a Row

After Wedbush and Nomura gave Argenx Se (NASDAQ: ARGX) a Buy rating last month, the company received another Buy, this time from Cowen & Co. Analyst Boris Peaker maintained a Buy rating on Argenx Se today. The company’s shares opened

Cowen & Co. Thinks Y-Mabs Therapeutics Inc’s Stock is Going to Recover

In a report released today, Boris Peaker from Cowen & Co. maintained a Buy rating on Y-Mabs Therapeutics Inc (NASDAQ: YMAB). The company’s shares closed yesterday at $21.60, close to its 52-week low of $20.03. According to TipRanks.com, Peaker is

Cowen & Co. Believes Endocyte (NASDAQ: ECYT) Won’t Stop Here

Cowen & Co. analyst Boris Peaker maintained a Buy rating on Endocyte (NASDAQ: ECYT) today. The company’s shares opened today at $18.89, close to its 52-week high of $20.85. According to TipRanks.com, Peaker is a 5-star analyst with an average

Alimera (ALIM) Gets a Buy Rating from Cowen & Co.

Cowen & Co. analyst Boris Peaker maintained a Buy rating on Alimera (NASDAQ: ALIM) today and set a price target of $3. The company’s shares opened today at $1. According to TipRanks.com, Peaker is a 5-star analyst with an average

Emergent Biosolutions (EBS) Receives a Hold from Cowen & Co.

Cowen & Co. analyst Boris Peaker maintained a Hold rating on Emergent Biosolutions (NYSE: EBS) today and set a price target of $49. The company’s shares opened today at $62.53, close to its 52-week high of $62.85. According to TipRanks.com,